The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. This study investigated the effect of nicotinamide mononucleotide (NMN) supplementation on immunosenescence in middle-aged and elderly people through a placebo-controlled long-range clinical trail, aiming to provide a new method to improve immunosenescence. The effects of NMN supplementation on glucose and lipid metabolic indexes, body composition and telomere length of peripheral blood cells are also investigated, which may open up new ideas for the prevention and treatment of glucose and lipid metabolic diseases.
Age 50-70 years with overweight or obesity (BMI 24kg/m2);
At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c <7% without glucose-lowering drug therapy;
Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
Patients with tumours;
Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
Severe cardiovascular disease or cardiac insufficiency;
Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg;
Qing Su
Lead sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor institution